125068-54-4
| 中文名稱 | 125068-54-4 |
|---|---|
| 中文同義詞 | 化合物NSP-805;5-甲基-6-(4-((2-甲基-3-氧代環(huán)戊-1-烯-1-基)氨基)苯基)-4,5-二氫噠嗪-3(2H)-酮;化合物NSP-805,10 MM DMSO 溶液 |
| 英文名稱 | NSP 805 |
| 英文同義詞 | NSP 805;3(2H)-Pyridazinone, 4,5-dihydro-5-methyl-6-[4-[(2-methyl-3-oxo-1-cyclopenten-1-yl)amino]phenyl]-;Inhibitor,NSP805,inhibit,NSP-805,NSP 805,Phosphodiesterase (PDE);5-Methyl-6-(4-((2-methyl-3-oxocyclopent-1-en-1-yl)amino)phenyl)-4,5-dihydropyridazin-3(2H)-one;NSP-805, 10 mM in DMSO |
| CAS號 | 125068-54-4 |
| 分子式 | C17H19N3O2 |
| 分子量 | 297.35 |
| EINECS號 | |
| 相關(guān)類別 | |
| Mol文件 | 125068-54-4.mol |
| 結(jié)構(gòu)式 |  |
125068-54-4 性質(zhì)
| 密度 | 1.30±0.1 g/cm3(Predicted) |
|---|---|
| 儲存條件 | Store at -20°C |
| 溶解度 | 溶于二甲基亞砜 |
| 形態(tài) | 固體 |
| 酸度系數(shù)(pKa) | 13.84±0.60(Predicted) |
| 顏色 | 淺黃至黃色 |
In isolated guinea pig left atria, NSP-805 shows positive inotropic EC 50 value in order of potency of 0.18 μM. The in vitro positive inotropic effects of NSP-805 is accompanied by increases in tissue cyclic AMP and abolished by carbachol.
In anesthetized dogs, intravenous (i.v.) injection of NSP-805 produces dose-dependent increases in left ventricular VVdp/dtmax and decreases in aortic blood pressure (ABP) with relatively small increases in heart rate (HR). The ED 50 value for LVdP/dtmax of NSP-805 is 12 μg/kg. When the drugs is administered intraduodenally to anesthetized dogs, the ED 50 value for LVdP/dtmax of NSP-805, is approximately 10 μg/kg. In the propranolol-induced heart failure model, NSP-805 completely improves the hemodynamic state of heart failure to normal levels. NSP-805(100 μg/kg) reduces systemic blood pressure significantly, but the increase of chorio-retinal blood flow is less than that at the low dose of NSP-805 (40 μg/kg) in rabbit eyes.
安全信息
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-19102 | NSP-805 | 125068-54-4 | 1 mg | 800元 |
| 2026/06/05 | HY-19102 | 125068-54-4 NSP-805 | 125068-54-4 | 5mg | 2000元 |